Here are six updates from gastroenterology companies and practices from the past week:
Nearly 90 percent of U.S. gastroenterologists are open to leveraging artificial intelligence to improve colonoscopies, according to a study published in Endoscopy International Open.
Independent gastroenterology practice Charleston (S.C.) GI opened an endoscopy center in Summerville, S.C.
Takeda has entered into a $1.04 billion licensing agreement with Arrowhead Pharmaceuticals around its phase 2 therapy ARO-AAT, which was designed to treat alpha-1 antitrypsin-associated liver disease.
The University of Minnesota in Minneapolis launched a new clinical trial that will use CRISPR genetic engineering to treat metastatic gastrointestinal solid tumor cancer.
Nearly 1 in 12 colonoscopies without an associated intervention ended with an out-of-network claim, according to a new study published in the Annals of Internal Medicine.
Middletown, Conn.-based Middlesex Health recently opened its Center for Digestive Health to unite all its gastrointestinal services.
More articles on surgery centers:
Colonoscopy screening numbers starting to rebound — 10 GI industry key notes
5 most-read stories in GI this week — Gastro Health 1st to use endoscopic gastroscope in US
Florida Digestive Health Specialists expands presence